Scholarlink

Background <p>Chronic back pain remains a leading cause of disability worldwide, with high societal and healthcare costs and limited effective treatment options. More than 50% of people with chronic back pain also report insomnia symptoms. Melatonin, primarily known for its use in treating insomnia and jetlag, has shown promising effects as a pain medication in chronic non-musculoskeletal pain conditions. We aim to determine the efficacy of 6&#xa0;weeks of melatonin compared with placebo in reducing average pain intensity in patients with chronic disabling back pain.</p> Method <p>The Melatonin for Chronic Back Pain (MOCHA) trial is a 1:1 randomized, placebo-controlled, double-blind, superiority trial including 220 patients with chronic disabling back pain randomized to either 10&#xa0;mg (given as two 5&#xa0;mg tablets) melatonin daily for 6&#xa0;weeks or an identically looking placebo tablet. The primary outcome is the between-group difference in change in average pain intensity during the last 7&#xa0;days from baseline to 6&#xa0;weeks. Secondary outcomes include insomnia severity, back pain-related disability, global perceived effect, physical and mental health, and pain sensitivity. Exploratory outcomes are physiological sleep metrics assessed with ear electroencephalography (EEG).</p> Discussion <p>This trial evaluates the efficacy of melatonin, an inexpensive and widely available intervention that could potentially reduce pain and sleep problems in a population with few effective treatment options available.</p> <p>Trial registration</p> <p>CTIS EU-CT 2023-503530-41-00. Registered on March 4th, 2024.</p> <p>ClinicalTrials.gov NCT06476392. Registered on June 20th, 2024.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Melatonin for chronic back pain (the MOCHA trial): study protocol for a randomized, double-blind, placebo-controlled trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月17日

查看全文
  • Kübra Kilic,
  • Henrik Bjarke Vægter,
  • Karin Due Bruun,
  • Werner Vach,
  • Jan Hartvigsen,
  • Bart Willem Koes,
  • Preben Kidmose,
  • Jens Søndergaard,
  • Jonas Bloch Thorlund

摘要

Background

Chronic back pain remains a leading cause of disability worldwide, with high societal and healthcare costs and limited effective treatment options. More than 50% of people with chronic back pain also report insomnia symptoms. Melatonin, primarily known for its use in treating insomnia and jetlag, has shown promising effects as a pain medication in chronic non-musculoskeletal pain conditions. We aim to determine the efficacy of 6 weeks of melatonin compared with placebo in reducing average pain intensity in patients with chronic disabling back pain.

Method

The Melatonin for Chronic Back Pain (MOCHA) trial is a 1:1 randomized, placebo-controlled, double-blind, superiority trial including 220 patients with chronic disabling back pain randomized to either 10 mg (given as two 5 mg tablets) melatonin daily for 6 weeks or an identically looking placebo tablet. The primary outcome is the between-group difference in change in average pain intensity during the last 7 days from baseline to 6 weeks. Secondary outcomes include insomnia severity, back pain-related disability, global perceived effect, physical and mental health, and pain sensitivity. Exploratory outcomes are physiological sleep metrics assessed with ear electroencephalography (EEG).

Discussion

This trial evaluates the efficacy of melatonin, an inexpensive and widely available intervention that could potentially reduce pain and sleep problems in a population with few effective treatment options available.

Trial registration

CTIS EU-CT 2023-503530-41-00. Registered on March 4th, 2024.

ClinicalTrials.gov NCT06476392. Registered on June 20th, 2024.